Smoking Cessation Aids Equally Effective in Those With Mental Health Conditions
06 Jun 2024
Clinical Result
THURSDAY, June 6, 2024 -- Popular smoking cessation aids are equally effective in those with or without a history of mental health conditions, according to a study published online June 4 in PLOS Mental Health.
Sarah E. Jackson, Ph.D., from University College London, and colleagues examined whether the real-world effectiveness of popular smoking cessation aids differs between users with and without a history of mental health conditions. The analysis included 5,593 adults (2,524 with a history of at least one mental health condition) who had smoked regularly within the past year and had attempted to quit at least once in the past year.
The researchers found that participants with a history of mental health conditions were significantly more likely to report using vaping products (38.8 versus 30.7 percent without a mental health condition), prescription nicotine replacement therapy (4.8 versus 2.7 percent), and websites (4.0 versus 2.2 percent). When adjusting for covariates and use of other cessation aids, those who used vaping products (odds ratio [OR], 1.92), varenicline (OR, 1.88), or heated tobacco products (OR, 2.33) had significantly higher odds of quitting successfully compared with those who did not report using these aids.
"In conclusion, use of vaping products, varenicline, or heated tobacco products in a quit attempt was associated with significantly greater odds of successful cessation, after adjustment for use of other cessation aids and potential confounders," the authors write. "There was no evidence to suggest the effectiveness of any popular cessation aid differed according to the user’s history of mental health conditions."
Abstract/Full Text
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Indications
-Targets
-Drugs
Hot reports
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.